|Bid||15.00 x 1200|
|Ask||50.00 x 1000|
|Day's Range||30.43 - 31.99|
|52 Week Range||13.60 - 54.00|
|Beta (3Y Monthly)||2.56|
|PE Ratio (TTM)||358.09|
|Earnings Date||Feb 21, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||52.50|
STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today provided preliminary sales results for the fourth quarter ended December 28, 2018. The Company expects fourth quarter ICL net sales to increase approximately 42% over the prior year period. Total net sales for the fourth quarter are expected to be approximately $31.2 million and total net sales for fiscal 2018 are expected to be approximately $124.0 million, representing approximately 37% growth over fiscal 2017.
Players in the Healthcare sector gained from aging population, expanding government business, technological investment, strong demand for its product and services and industry consolidation.
Strong demand for Express Scripts' (ESRX) solutions like SafeGuardRx, 90-day supply for chronic medications, exclusive Accredo Specialty Pharmacy and advanced opioid solutions buoy optimism.
Express Scripts (ESRX) and Walmart (WMT) collaborate to increase affordable access of the expensive prescription drugs for insured and uninsured patients.
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow over 700 of the best-performing investors and by analyzing their 13F filings, we can determine the stocks that they are collectively bullish […]
Masimo (MASI) gains from solid prospects in the SET Pulse Oximeter platform. However, cutthroat competition in the MedTech space is likely to hurt the stock.
Pacific Biosciences (PACB) is likely to gain from strong prospects in the Sequel System platform. However, the company faces cutthroat competition in the DNA sequencing market.
STAAR Surgical Company (NASDAQ:STAA) is a stock with outstanding fundamental characteristics. When we build an investment case, we need to look at the stock with a holistic perspective. In the Read More...
Accuray's (ARAY) benefits from growing adoption of non-surgical treatment options among cancer patients and increasing demand for its latest offerings.
Ecolab (ECL) to leverage on Bioquell's innovative bio-decontamination and isolator platforms for residue-free surface decontamination.
Cardinal Health (CAH) helps hospitals identify hidden savings, improve patient outcomes and drive supply chain efficiencies.
Solid prospects in the Rave Genomics platform are likely to provide Medidata (MDSO) a competitive edge in the MedTech space.
When determining position size for a swing trade, a few factors come into play. The market environment and risk on the individual swing trade are paramount.
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
NEW YORK, Nov. 02, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the first patient implants of the company’s Visian Toric Implantable Collamer Lenses (TICLs) in the U.S. by Brinton Vision in St. Louis, Missouri, and Parkhurst NuVision in San Antonio, Texas. The TICL was approved in the U.S. by the FDA on September 13, 2018, and the first patient implants occurred on October 22, 2018. The Visian TICL has been approved and available for patients outside of the U.S. since 2002.
Staar Surgical (STAA) delivered earnings and revenue surprises of 333.33% and 5.55%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Monrovia, California-based company said it had net income of 3 cents. Earnings, adjusted for non-recurring costs, were 7 cents per share. The maker of implantable lenses posted ...